Investigators examined the mRNA signature foundation associated with the pro-inflammatory phenotype of depression, along with the differential signatures linked to depression subtypes and the impact of antidepressant agents.
Higher childhood neighborhood quality and childhood friendliness scores have been shown to be significantly associated with a lower risk for the development of depressive symptoms in adults.
In matched full and half siblings who are at high risk for major depression, individuals reared in adopted homes—which in Sweden are selected because of their high-quality rearing environment—have a significantly lower risk for major depression compared with individuals reared in their home environment.
In elderly patients with remitted MDD, a 10-day course of standalone bilateral dorsolateral prefrontal cortex anodal transcranial direct current stimulation was well tolerated but failed to improve global cognition or working memory at 14 days’ or at 90 days’ postintervention.
In patients with major depressive disorder, higher body mass index and being obese/overweight were associated with a more robust acute antidepressant response to treatment with ketamine.
Asian American college students were more likely to be diagnosed with depression than were European American and African American students. Additionally, female and LGBQ participants had higher depressive symptom scores, more likely to be diagnosed with depression, and more likely to have a history or suicidal ideation and suicide attempts.
Loss of interest and reduction of activity reported among patients with major depressive disorder (MDD) are predictive of a poor response to antidepressant monotherapy with escitalopram and are indicative of the need for aripiprazole augmentation.
Intranasal esketamine is unlikely to be cost-effective for the management of treatment-resistant depression in the United States unless its price declines by >40%. Its price would need to drop from its current price of $240 per dose to ≤$140 per dose.
In patients with treatment-resistant depression, use of SAINT—a high-dose, resting-state, fcMRI–guided iTBS protocol is safe and well tolerated, and is associated with a high rate of remission from depression.
In adult patients with major depressive disorder or bipolar disorder, the use of intravenous ketamine is generally well tolerated and safe when administered mainly as an acute treatment.
